Тразограф

Quick links to important sections

Тразограф

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Тразограф

What is Тразограф? Defining the Diagnostic Agent

Property Description
Active Ingredient Sodium Amidotrizoate (Diatrizoate Sodium)
Form Sterile Aqueous Solution
Pharmacological Class Radiopaque Contrast Agent
Common Use Diagnostic Imaging Enhancement
Origin Synthetic

Тразограф is a synthetic, specialized prescription-only medication that functions exclusively as a Radiopaque Contrast Agent. It is not a therapeutic drug intended to treat illness but is utilized as a diagnostic aid to enhance visualization of internal anatomy during radiographic examinations, such as X-rays and computed tomography (CT scans). The agent belongs to the class of Iodinated Contrast Media, distinguished by its ability to absorb radiation efficiently. It maintains a recognized role as a vital diagnostic agent for functional health systems.


Composition and Form: The Sodium Amidotrizoate Solution

The product’s single active ingredient is Sodium Amidotrizoate, which is the sodium salt of diatrizoic acid. This substance is an ionic organoiodine compound, specifically designed to contain a high concentration of the element Iodine. Тразограф, available as a sterile aqueous solution, can be administered via multiple routes, including intravascular injection (intravenously or intra-arterially) and administration into the gastrointestinal tract (orally or rectally), depending on the required diagnostic procedure. This versatility makes it a reliable choice for complex diagnostic scenarios.


How Does Тразограф Function in Imaging?

The core function of Тразограф is to achieve radiodensity enhancement within targeted anatomical spaces. This effect is produced by the Iodine atoms within the Sodium Amidotrizoate molecule, which, due to their high atomic weight, effectively absorb or block X-ray photons. By temporarily filling structures like blood vessels or the urinary tract, the agent allows the physician to clearly outline and distinguish these areas from surrounding soft tissues. This mechanism ensures that the size, shape, and integrity of critical structures are made visible for accurate medical assessment.

Regulatory References

  1. Model List of Essential Medicines

What side effects are possible with Тразограф?

Possible Side Effects and Safety Information

The safety profile of Тразограф (Sodium Amidotrizoate) is based on classifications established by government regulatory agencies and reflects patterns observed across the clinical use of iodinated contrast media. The nature and frequency of possible adverse reactions are formally classified according to System Organ Classes (SOC) and predefined frequency categories.

Officially Documented Adverse Reactions by Frequency

The most commonly documented adverse reactions, classified as Common (ge 1/100), involve Gastrointestinal disorders, specifically nausea, vomiting, diarrhea, and abdominal cramping. Reactions classified as Uncommon (1/100 to 1/1,000) may include milder hypersensitivity reactions such as urticaria (hives) and pruritus (itching).

Rare reactions (1/1,000 to 1/10,000) can involve hypotension (low blood pressure) and tachycardia (increased heart rate). The most serious reactions, such as anaphylactic shock or cardiac arrest, are classified as Very Rare.

Serious Adverse Reactions and Safety Patterns

Official labeling highlights the risks of severe Immune system disorders, including potentially life-threatening anaphylactoid/anaphylactic reactions, which typically occur within minutes to hours of administration. Safety information also documents a risk of transient renal impairment and acute kidney injury, particularly in patients with pre-existing renal dysfunction.

Specific patient populations have documented safety considerations: a note exists regarding the risk of thyroid dysfunction in pediatric patients due to iodine load. Furthermore, the agent is contraindicated in individuals with known severe hypersensitivity to Diatrizoate, and certain routes, such as intrathecal (spinal canal) administration, are explicitly prohibited in the regulatory safety information.

Overdose and Emergency Response

Overdose with Sodium Amidotrizoate (Тразограф), a radiopaque contrast agent, is defined by regulatory authorities as the consequence of excessive dosing, an overly rapid rate of infusion, or impaired elimination. The official labeling documents systemic and organ-specific manifestations demanding immediate intervention.

Overdose may initially present as hypervolemia (excess fluid volume) and severe electrolyte imbalance due to the agent's high osmotic load. Documented severe outcomes include acute kidney injury (AKI), pulmonary edema, and cardiovascular instability like congestive heart failure. Central nervous system effects such as seizures and coma are also officially noted risks. Individuals with pre-existing renal impairment, cardiac failure, or multiple myeloma carry an increased risk of severity.

Seek immediate medical attention and contact emergency services immediately if a severe overdose is suspected or if any life-threatening symptoms occur. Regulatory documents explicitly state that no specific antidote is known for this agent. Management is strictly symptomatic and supportive, focused on continuous cardiovascular and renal function monitoring. Supportive measures may include the correction of fluid imbalances and, in cases of severe intoxication, procedural elimination steps such as hemodialysis may be required.

Therapeutic Uses of Тразограф

Main Uses and Applications

Тразограф (Trazograf) is an ionic radiopaque contrast medium used primarily in diagnostic imaging. It contains sodium amidotrizoate and meglumine amidotrizoate, which are salts of amidotrizoic acid. These substances absorb X-rays, increasing the contrast of internal structures and allowing for clearer visualization during various medical examinations.

Cardiovascular Imaging

One of the primary applications of this agent is in the visualization of the heart and blood vessels. When injected into the bloodstream, it helps outline the anatomy of the vascular system, assisting in the detection of narrowing, blockages, or structural abnormalities. Common procedures include:

  • Angiography: Visualizing arteries in various parts of the body.
  • Aortography: Examination of the aorta, the body's main artery.
  • Ventriculography: Assessing the function and structure of the heart's ventricles.

Urinary Tract Examination

Тразограф is frequently used in urography to evaluate the kidneys, ureters, and bladder. It helps in identifying stones, tumors, or anatomical variations by highlighting the path of fluid through the urinary system as the contrast is excreted by the kidneys.

Imaging of Body Cavities and Ducts

Beyond the vascular and urinary systems, this contrast agent is utilized to examine various cavities and ductal structures within the body:

  • Arthrography: Evaluation of joint spaces to detect internal injuries or degenerative changes.
  • Cholangiography: Visualization of the bile ducts to check for obstructions such as gallstones.
  • Sialography: Examination of the salivary glands and ducts.
  • Hysterosalpingography: Assessment of the uterus and fallopian tubes.

Computed Tomography (CT) Enhancement

In computed tomography, the agent is used to enhance the contrast of various organs and tissues. This allows for a more detailed differentiation between normal anatomy and potential lesions, improving the diagnostic accuracy of the scan.

Benefits in Diagnostic Procedures

The integration of Тразограф into diagnostic imaging provides several clinical advantages:

  • Enhanced Clarity: By increasing the radiopacity of blood and body fluids, it provides sharp definition of internal organs and vessels that would otherwise be difficult to see on standard X-rays.
  • Structural Detail: It enables the identification of fine anatomical details, which is essential for diagnosing complex vascular or organ-related conditions.
  • Functional Assessment: In procedures like urography, the movement of the contrast medium allows for a basic assessment of organ function, such as the excretory capacity of the kidneys.

Regulatory References

  1. DailyMed prescribing information

Eligibility and Restrictions for Use

Who Can and Cannot Use Тразограф?

The population eligibility rules for Тразограф (Diatrizoate Meglumine and Diatrizoate Sodium Solution) are defined by official government regulatory documents based on contraindications and conditional use.

Absolute Contraindications

Use of the agent is strictly prohibited in:

  • Patients with manifest hyperthyroidism.
  • Individuals with known hypersensitivity to salts of diatrizoic acid.
  • Patients with a suspected esophagotracheal fistula.

Furthermore, the medicine is contraindicated for intravenous or intramuscular administration; it is approved only for oral or rectal diagnostic procedures.


Conditional and Restricted Use

Population/Condition Regulatory Restriction
Newborns, Infants, Dehydrated Patients Prohibited from using the undiluted agent due to risk of osmotic fluid shift.
Children under 10 Requires mandatory dilution for administration.
Pregnant Women Safety has not been established; use is permitted only if essential to the patient's welfare.
Cachectic Elderly Persons Dilution with water is recommended to mitigate the risk of fluid loss.

Eligibility also requires that electrolyte imbalances be corrected prior to administration to avoid complications.

What should I know about interactions with other medicines?

Trazograph Interactions with Other Medicines and Products

Interactions with Trazograph are classified based on the officially documented risk and effect on drug exposure or physiological response. Consult regulatory information for complete details on all known interactions.


Contraindicated Combinations

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is strictly prohibited, requiring a two-week washout period before starting Trazograph and a one-week period after stopping it. Combining Trazograph with the herbal supplement St. John's Wort is also contraindicated.

Pharmacokinetic Exposure Changes

The plasma concentration of Trazograph can be significantly altered by co-administered medicines, primarily through metabolic pathways involving the CYP3A4 enzyme. Strong inhibitors of CYP3A4 (e.g., certain antifungals) are documented to increase Trazograph exposure, while strong inducers of CYP3A4 (e.g., certain anticonvulsants) are documented to decrease Trazograph exposure. Changes in exposure may necessitate regulatory guidance.

Pharmacodynamic and Substance Interactions

Official labeling indicates an enhanced risk of effects when Trazograph is combined with other agents. Co-ingestion with alcohol and other CNS depressants (e.g., sedatives) is restricted due to the potential for intensified central nervous system effects. Combining Trazograph with serotonergic agents is noted to increase the risk of serotonin-related adverse events. Furthermore, caution is advised regarding antihypertensive medicines due to the potential for additive blood pressure lowering.

Mechanism of Action

How Тразограф Works: Mechanism of Action


The function of Тразограф (Sodium Amidotrizoate) is based on a physicochemical mechanism, lacking interaction with typical biological targets like receptors or enzymes. The agent's action centers on the Iodine atoms within the molecule, which possess a high atomic weight (Z=53). When delivered, the iodine atoms physically intercept and attenuate (absorb or scatter) X-ray photons passing through the body. This physical property results in a localized, non-biological increase in radiodensity, which is the physiological change necessary for image contrast.

The efficacy depends on the Anatomical Space Filling mechanism, utilizing the body’s natural Systemic Distribution pathways. The solution is rapidly carried by the blood flow or delivered directly to fill the internal space (lumen) of the structure being examined. This passive filling action ensures the uniform delivery of the radiodense material, resulting in the demarcation of internal structure contours for physical assessment. The mechanism is inherently constrained by the local concentration of iodine; if diluted, the X-ray attenuation effect is reduced, leading to suboptimal contrast and decreased differentiation from surrounding soft tissue.

Dosage and Administration Information

How to Use Тразограф: Official Administration Guidelines

The administration of Тразограф (Diatrizoate Meglumine and Diatrizoate Sodium Solution) is strictly procedural, defining its role as a single-use contrast agent for diagnostic imaging of the gastrointestinal (GI) tract. The official instructions detail the required route, preparation, and timing relative to the scheduled procedure.


Administration Protocol

The solution is approved only for Oral, Rectal (enema), or Enterostomy Instillation. This formulation is explicitly not to be used for injection (parenteral) administration.

Dosing and Preparation: The administration is a single-use volume, not a continuous course of treatment. The standard adult oral dose for general radiography ranges from 30 mL to 90 mL. For use as an adjunct in CT body imaging, 240 mL of a dilute solution is required, typically prepared by mixing 25 mL to 77 mL of the agent in 1 L of water.

Dilution Requirements: Dilution is mandatory for rectal administration and is specifically recommended for elderly or debilitated adults (a 1:1 dilution with water). Pediatric dose volumes are also adjusted by age group and may require a 1:1 or 1:3 dilution. Water, carbonated beverages, or milk are approved diluents.

Timing: The oral dose for CT imaging is typically administered 15 to 30 minutes before the procedure. Any solution unused from an opened container must be discarded after 72 hours.

Recent Clinical Evidence

Recent Clinical Evidence for Тразограф (Diatrizoate Meglumine and Diatrizoate Sodium)

Тразограф is a brand name for an iodinated, ionic, high-osmolar radiocontrast medium primarily used to enhance visibility in X-ray and Computed Tomography (CT) imaging. Its clinical use is supported by decades of experience with its active components, Diatrizoate meglumine and Diatrizoate sodium.

Diagnostic Utility and Applications

Clinical studies and routine practice confirm the agent's utility across various diagnostic procedures, including:

  • Angiography: Used to visualize blood vessels, which may assist in assessing blockages, narrowing, or abnormal connections within the circulatory system (arteries and veins).
  • Urography: Employed to enhance images of the urinary tract (kidneys, ureters, and bladder) for evaluation of structural issues like tumors, cysts, or stones.
  • Gastrointestinal Imaging: It may be administered orally or rectally to outline the internal contours of the esophagus, stomach, small intestine, and colon, often when perforation is suspected, as it is water-soluble and is not absorbed by the body.

Comparative Safety and Modern Practice

Historically, high-osmolar ionic contrast agents, such as those in Тразограф, have been associated with a higher incidence of adverse effects like a feeling of warmth, nausea, or vomiting compared to newer, non-ionic, low-osmolar or iso-osmolar agents. Due to advancements in contrast media, contemporary clinical practice often favors the lower-osmolar non-ionic agents for intravascular use, especially in patients with pre-existing risk factors such as renal impairment or a history of prior contrast reaction. However, the diatrizoate formulation remains a standard, effective option for specific uses like certain gastrointestinal studies, particularly where a water-soluble agent is necessary. Research efforts continue to focus on defining optimal patient selection and hydration strategies to mitigate the risk of contrast-induced nephropathy (CIN) associated with all iodinated contrast agents.

Frequently Asked Questions (FAQ)

Common questions about Тразограф (FAQ)

Q: Is Тразограф an antibiotic or an antiviral?

According to official product information, Тразограф is classified as an iodinated radiopaque contrast agent. It works through a physical mechanism (called X-ray attenuation) to enhance images during diagnostic procedures, and it is not categorized as an antibiotic or an antiviral medicine.


Q: How quickly should someone expect to feel effects after starting Тразограф?

The intended effect of the agent is to provide contrast for diagnostic imaging. This occurs rapidly, almost immediately, as the solution physically fills the gastrointestinal tract during the procedure, making the effect immediate and non-subjective.


Q: Is Тразограф safe for people with known kidney issues?

Official regulatory documents note that this type of agent is primarily removed from the body by the kidneys. If a patient has severe impairment of kidney function, the official information states that excretion via the liver and small intestine increases.


Q: Can older adults (seniors) generally use Тразограф?

Yes, official instructions include specific dilution guidelines for administration to elderly or debilitated adult patients. This indicates that its use is generally permitted in this population, but with specific procedural precautions.


Q: Does taking Тразограф require any changes to diet?

The official documentation does not list specific food prohibitions, but notes that approved diluents for the solution include water, carbonated beverages, or milk. Additionally, conditions that may promote gastrointestinal hyperacidity, such as stress or fasting, should be considered in the administration protocol.


Q: What are the main ingredients in Тразограф besides the active substance?

Besides the active substances, which are diatrizoate meglumine and diatrizoate sodium, the solution typically contains inactive ingredients. These commonly include buffering agents, such as monobasic sodium phosphate, and sequestering agents like edetate calcium disodium.


Q: How long does the effectiveness of Тразограф wear off over time?

The agent's contrast-enhancing effect is rapid and lasts only as long as the solution is physically present in the gastrointestinal tract during the imaging procedure. The substance itself is primarily excreted from the body by the kidneys.


Q: What are the most commonly reported side effects of Тразограф?

According to regulatory adverse reaction data for enteral contrast agents, most reactions are mild and temporary. These commonly reported effects include temporary issues such as nausea, vomiting, diarrhea, stomach cramps, and heartburn.


Q: Is it normal to feel tired when first starting Тразограф?

Fatigue or general tiredness is not typically listed as a common side effect in official documents. However, because the solution is highly concentrated (hypertonic), it may cause fluid loss. Monitoring for signs of weakness is described in official warnings.


Q: Does Тразограф cause weight gain or weight loss?

The official documentation advises that patients be monitored for signs of thyroid problems or fluid and electrolyte disturbances, both of which can potentially be associated with a change in weight. Changes in weight are not listed as a common adverse reaction.


Q: Are there any specific foods that should be avoided while taking Тразограф?

The official instructions only mention approved diluents and do not list specific food prohibitions. Any specific dietary requirements before the procedure would be determined by the healthcare provider.


Q: Is Тразограф considered safe to use during pregnancy?

Regulatory data indicates that there are no adequate, controlled human studies available on the use of this agent in pregnant women. Official labeling advises that the agent should only be used during pregnancy if a qualified healthcare provider determines that it is clearly needed.


Q: Has Тразограф been approved by the FDA or other major regulatory bodies?

Yes, the product has received approval from major regulatory bodies as a radiopaque contrast agent for oral or rectal administration in diagnostic radiology.


Q: Why do doctors prescribe Тразограф instead of just lifestyle changes?

This agent is not prescribed as a therapeutic drug to treat a chronic illness or condition. It is indicated strictly as a diagnostic tool used to enhance the visibility of the gastrointestinal tract during X-ray or CT imaging procedures.


Q: Is it necessary to have routine blood tests while on Тразограф?

Routine, continuous blood tests are not generally required since the agent is single-use. However, official information notes that certain thyroid function tests, which rely on iodine estimations, may not accurately reflect thyroid function for up to six months after the administration of this agent.


Q: Does Тразограф affect the ability to drive or operate machinery?

Official documentation lists potential adverse reactions such as dizziness and headache, which may temporarily impact the ability to safely drive or operate machinery.


Q: Is the 'how it works' explanation for Тразограф publicly available in official documents?

Yes, the official prescribing information includes a detailed description of the drug's mechanism of action. This explains that the function is based on the physical property of its iodine content to attenuate, or absorb, X-rays.


Q: Does Тразограф interact with common vitamins or herbal supplements?

The official label does not report any moderate or major drug interactions with common vitamins or herbal supplements. However, it specifically notes that the agent can interfere with certain laboratory tests, such as thyroid function tests.


Q: Can people with a history of [Specific Medical Issue] use Тразограф?

Use is strictly restricted for individuals with a known hypersensitivity to the active diatrizoate salts. Caution is also advised for patients who have a history of conditions such as hyperthyroidism, goiter, bronchial asthma, or general allergies.


Q: What are the official restrictions for who cannot use Тразограф?

The primary official restriction (contraindication) for the use of this agent is a known hypersensitivity (severe allergic reaction) to the active ingredients, which are the diatrizoate salts.


Q: Is Тразограф a prescription-only medicine?

Yes, as a radiopaque diagnostic agent intended for use in specialized medical procedures, it is classified as a prescription-only medicine.


Q: Are allergic reactions to Тразограф common?

Allergic or anaphylactoid reactions are a possibility with this type of agent. However, most adverse reactions reported for enteral diagnostic radiopaque agents are officially described as being mild and temporary.


Q: What are the potential mental or mood side effects of Тразограф?

The official label does not specify common mental or mood side effects. However, because the agent can cause fluid and electrolyte disturbances, signs of these imbalances (such as confusion or mood changes) are noted.


Q: Is the research evidence for Тразограф based on human studies?

The regulatory approval of this product is based on both clinical (human) and non-clinical studies. These studies were conducted to demonstrate its function and utility as an iodinated radiopaque contrast agent for diagnostic imaging.


Q: Can Тразограф affect fertility in men or women?

Official nonclinical toxicology data indicates that long-term animal studies have not been performed to evaluate the agent’s potential to impair fertility in either males or females.


Q: What is the classification of Тразограф (e.g., controlled substance, non-narcotic)?

Тразограф is officially classified as a radiopaque contrast agent intended purely for diagnostic purposes. It is not listed or categorized as a controlled substance.


Q: Is it common for people to take Тразограф for several months?

No, official use guidelines state that the administration is a single-use volume for a diagnostic procedure. It is not intended for a continuous course of treatment over a period of several months.


Q: Are there pediatric (children's) use restrictions for Тразограф?

Yes, the official documentation includes specific dilution guidelines and warnings for use in infants and children. It also notes that certain pediatric groups may be at an increased risk for specific adverse effects, such as temporary thyroid dysfunction.


Q: Does Тразограф interact with hormonal birth control?

The official label does not specify any major or moderate drug interactions with common hormonal contraceptive products.


Q: What kind of studies led to the approval of Тразограф?

The regulatory approval of the agent is supported by clinical and non-clinical studies. These studies demonstrated its effective function as an iodinated radiopaque contrast agent for the intended use in diagnostic imaging procedures.

How should Тразограф be stored and disposed of?

How to Store and Dispose of Тразограф?

This section outlines the official, labeled requirements for the storage, stability, and disposal of Тразограф.

Storage and Handling Requirement Official Classification
Temperature Range Do not store at a temperature higher than 30 °C.
Protection Must be protected from freezing, light, and secondary X-rays.
Accessibility Store in a location that is inaccessible to children.
Stability Period The product maintains a 5-year shelf life when unopened.

Official documents strictly prohibit freezing the solution and mandate protection from light and X-ray exposure to preserve product integrity. The drug must not be used past the expiration date marked on the package. Although not intended for long-term storage under heat, a limited quantity may be heated to 37 C for up to three months for immediate examination use, provided daylight protection is maintained during this period.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Тразограф found in:

A-Z Index: